First Trust Advisors LP Has $1.29 Million Stake in Sangamo Therapeutics Inc (SGMO)

First Trust Advisors LP decreased its position in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 62.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 76,317 shares of the biopharmaceutical company’s stock after selling 128,233 shares during the quarter. First Trust Advisors LP owned 0.08% of Sangamo Therapeutics worth $1,294,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of SGMO. BlackRock Inc. grew its holdings in shares of Sangamo Therapeutics by 20.8% in the 2nd quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock worth $114,780,000 after purchasing an additional 1,391,067 shares during the last quarter. Nexthera Capital LP grew its holdings in shares of Sangamo Therapeutics by 35.7% in the 2nd quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock worth $15,150,000 after purchasing an additional 280,538 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Sangamo Therapeutics by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after purchasing an additional 234,346 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Sangamo Therapeutics by 21.0% in the 2nd quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock worth $18,286,000 after purchasing an additional 223,870 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Sangamo Therapeutics by 52.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 545,000 shares of the biopharmaceutical company’s stock worth $9,238,000 after purchasing an additional 188,000 shares during the last quarter. 63.13% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a report on Monday, November 19th. ValuEngine raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 16th. JPMorgan Chase & Co. lowered shares of Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. Finally, Guggenheim lowered shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a report on Friday, November 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $19.71.

Shares of NASDAQ:SGMO opened at $11.31 on Friday. Sangamo Therapeutics Inc has a 12 month low of $9.00 and a 12 month high of $27.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.32 and a current ratio of 6.32. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -16.16 and a beta of 3.10.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The firm had revenue of $23.56 million for the quarter, compared to analyst estimates of $26.96 million. During the same quarter in the prior year, the firm earned ($0.15) EPS. The company’s revenue was up 99.5% on a year-over-year basis. Analysts expect that Sangamo Therapeutics Inc will post -0.72 earnings per share for the current fiscal year.

In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $14.55, for a total transaction of $72,750.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 30,000 shares of company stock worth $392,000. Insiders own 1.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “First Trust Advisors LP Has $1.29 Million Stake in Sangamo Therapeutics Inc (SGMO)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/12/08/first-trust-advisors-lp-has-1-29-million-stake-in-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: What is a Roth IRA?

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply